Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination

Matteo Vergati, Vittore Cereda, Ravi A. Madan, James L. Gulley, Ngar Yee Huen, Connie Jo Rogers, Kenneth W. Hance, Philip M. Arlen, Jeffrey Schlom, Kwong Y. Tsang

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

We have previously shown that the suppressive function of regulatory T cells (Tregs) from peripheral blood mononuclear cells (PBMCs) is enhanced in patients with prostate cancer when compared with healthy individuals. Two phase II studies using the PSA-TRICOM vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) showed evidence of patient benefit in terms of enhanced survival. The Halabi nomogram has been used to predict survival (HPS) of patients with mCRPC treated with conventional chemotherapy or second-line hormonal therapy. Tregs from PBMCs of patients (n = 23) with mCRPC were obtained pre- and post-three monthly vaccinations, and analyzed for number, phenotype, and suppressive function. Changes post- versus pre-vaccination in these parameters were compared with 3-year survival and HPS. No differences in Treg numbers were observed post- versus pre-vaccination. Trends (P = 0.029) were observed between overall survival (OS) and a decrease in Treg suppressive function post- versus pre-vaccination. Trends were also observed in analyzing effector:Treg (CD4+CD25+CD127-FoxP3 +CTLA4+) ratio post- versus pre-vaccination with OS versus HPS. These data provide preliminary evidence for a possible association between improved OS and a decrease in Treg function when PBMCs are analyzed after three monthly vaccinations. Patients with an OS > HPS were more likely to have decreased Treg function following vaccine. Larger studies to confirm and extend these findings are warranted.

Original languageEnglish (US)
Pages (from-to)197-206
Number of pages10
JournalCancer Immunology, Immunotherapy
Volume60
Issue number2
DOIs
StatePublished - Feb 1 2011

Fingerprint

Regulatory T-Lymphocytes
Prostatic Neoplasms
Vaccination
Survival
Castration
Blood Cells
Vaccines
Nomograms
Phenotype
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Vergati, Matteo ; Cereda, Vittore ; Madan, Ravi A. ; Gulley, James L. ; Huen, Ngar Yee ; Rogers, Connie Jo ; Hance, Kenneth W. ; Arlen, Philip M. ; Schlom, Jeffrey ; Tsang, Kwong Y. / Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. In: Cancer Immunology, Immunotherapy. 2011 ; Vol. 60, No. 2. pp. 197-206.
@article{6c11387cf068486782520b0bd4403fc2,
title = "Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination",
abstract = "We have previously shown that the suppressive function of regulatory T cells (Tregs) from peripheral blood mononuclear cells (PBMCs) is enhanced in patients with prostate cancer when compared with healthy individuals. Two phase II studies using the PSA-TRICOM vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) showed evidence of patient benefit in terms of enhanced survival. The Halabi nomogram has been used to predict survival (HPS) of patients with mCRPC treated with conventional chemotherapy or second-line hormonal therapy. Tregs from PBMCs of patients (n = 23) with mCRPC were obtained pre- and post-three monthly vaccinations, and analyzed for number, phenotype, and suppressive function. Changes post- versus pre-vaccination in these parameters were compared with 3-year survival and HPS. No differences in Treg numbers were observed post- versus pre-vaccination. Trends (P = 0.029) were observed between overall survival (OS) and a decrease in Treg suppressive function post- versus pre-vaccination. Trends were also observed in analyzing effector:Treg (CD4+CD25+CD127-FoxP3 +CTLA4+) ratio post- versus pre-vaccination with OS versus HPS. These data provide preliminary evidence for a possible association between improved OS and a decrease in Treg function when PBMCs are analyzed after three monthly vaccinations. Patients with an OS > HPS were more likely to have decreased Treg function following vaccine. Larger studies to confirm and extend these findings are warranted.",
author = "Matteo Vergati and Vittore Cereda and Madan, {Ravi A.} and Gulley, {James L.} and Huen, {Ngar Yee} and Rogers, {Connie Jo} and Hance, {Kenneth W.} and Arlen, {Philip M.} and Jeffrey Schlom and Tsang, {Kwong Y.}",
year = "2011",
month = "2",
day = "1",
doi = "10.1007/s00262-010-0927-9",
language = "English (US)",
volume = "60",
pages = "197--206",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

Vergati, M, Cereda, V, Madan, RA, Gulley, JL, Huen, NY, Rogers, CJ, Hance, KW, Arlen, PM, Schlom, J & Tsang, KY 2011, 'Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination', Cancer Immunology, Immunotherapy, vol. 60, no. 2, pp. 197-206. https://doi.org/10.1007/s00262-010-0927-9

Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. / Vergati, Matteo; Cereda, Vittore; Madan, Ravi A.; Gulley, James L.; Huen, Ngar Yee; Rogers, Connie Jo; Hance, Kenneth W.; Arlen, Philip M.; Schlom, Jeffrey; Tsang, Kwong Y.

In: Cancer Immunology, Immunotherapy, Vol. 60, No. 2, 01.02.2011, p. 197-206.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination

AU - Vergati, Matteo

AU - Cereda, Vittore

AU - Madan, Ravi A.

AU - Gulley, James L.

AU - Huen, Ngar Yee

AU - Rogers, Connie Jo

AU - Hance, Kenneth W.

AU - Arlen, Philip M.

AU - Schlom, Jeffrey

AU - Tsang, Kwong Y.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - We have previously shown that the suppressive function of regulatory T cells (Tregs) from peripheral blood mononuclear cells (PBMCs) is enhanced in patients with prostate cancer when compared with healthy individuals. Two phase II studies using the PSA-TRICOM vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) showed evidence of patient benefit in terms of enhanced survival. The Halabi nomogram has been used to predict survival (HPS) of patients with mCRPC treated with conventional chemotherapy or second-line hormonal therapy. Tregs from PBMCs of patients (n = 23) with mCRPC were obtained pre- and post-three monthly vaccinations, and analyzed for number, phenotype, and suppressive function. Changes post- versus pre-vaccination in these parameters were compared with 3-year survival and HPS. No differences in Treg numbers were observed post- versus pre-vaccination. Trends (P = 0.029) were observed between overall survival (OS) and a decrease in Treg suppressive function post- versus pre-vaccination. Trends were also observed in analyzing effector:Treg (CD4+CD25+CD127-FoxP3 +CTLA4+) ratio post- versus pre-vaccination with OS versus HPS. These data provide preliminary evidence for a possible association between improved OS and a decrease in Treg function when PBMCs are analyzed after three monthly vaccinations. Patients with an OS > HPS were more likely to have decreased Treg function following vaccine. Larger studies to confirm and extend these findings are warranted.

AB - We have previously shown that the suppressive function of regulatory T cells (Tregs) from peripheral blood mononuclear cells (PBMCs) is enhanced in patients with prostate cancer when compared with healthy individuals. Two phase II studies using the PSA-TRICOM vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) showed evidence of patient benefit in terms of enhanced survival. The Halabi nomogram has been used to predict survival (HPS) of patients with mCRPC treated with conventional chemotherapy or second-line hormonal therapy. Tregs from PBMCs of patients (n = 23) with mCRPC were obtained pre- and post-three monthly vaccinations, and analyzed for number, phenotype, and suppressive function. Changes post- versus pre-vaccination in these parameters were compared with 3-year survival and HPS. No differences in Treg numbers were observed post- versus pre-vaccination. Trends (P = 0.029) were observed between overall survival (OS) and a decrease in Treg suppressive function post- versus pre-vaccination. Trends were also observed in analyzing effector:Treg (CD4+CD25+CD127-FoxP3 +CTLA4+) ratio post- versus pre-vaccination with OS versus HPS. These data provide preliminary evidence for a possible association between improved OS and a decrease in Treg function when PBMCs are analyzed after three monthly vaccinations. Patients with an OS > HPS were more likely to have decreased Treg function following vaccine. Larger studies to confirm and extend these findings are warranted.

UR - http://www.scopus.com/inward/record.url?scp=79151474414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79151474414&partnerID=8YFLogxK

U2 - 10.1007/s00262-010-0927-9

DO - 10.1007/s00262-010-0927-9

M3 - Article

C2 - 20976449

AN - SCOPUS:79151474414

VL - 60

SP - 197

EP - 206

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -